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Abstract 
Analysis of human monoclonal antibodies (mAbs) developed from influenza infected donors have enormously 
contributed to the identification of neutralization sensitive epitopes of influenza virus. The HA protein is a crucial 
target of neutralizing antibodies and at monoclonal level only Abs binding to HA have been able to neutralize the 
virus. In this study, eight A (H1N1)pdm 2009 seropositive patients within the age range of 20-50 years (median = 36 
years) were recruited. Two anti-HA mAbs secreting stable clones, 2D8 and 2F12 were established under optimized 
conditions from the peripheral blood mononuclear cells (PBMCs) of the volunteers.  These antibodies efficiently 
neutralized the homologous laboratory isolated strain of the pandemic virus as well as the reference strain. Our study 
suggests that the anti-HA antibodies derived from infected Indian patients display neutralization potential against the 
A(H1N1)pdm 2009 virus. This is the first ever study of generation of mAbs against the pandemic influenza virus 
involving the immune repertoire if Indian patients. Molecular characterization of the target regions will help in 
identifying potential immunogens in the Indian pandemic isolates and confer protective immunity against this virus. 
© 2015 The Authors. Published by Elsevier B.V. 
Selection and peer-review under responsibility of the 8th Vaccine Conference Organizing Committee. 
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1. Introduction 
Influenza A virus is a member of the Orthomyxoviridae family and it is one of the main causes of prevalent infection 
of the   respiratory tract in humans. The susceptibility to influenza illness is most common in immunologically naive 
infants, immunocompromised individuals and elderly1. The virulence of influenza A virus is because of its easy spread 
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by aerosol; the frequent changes in the viral antigens by antigenic drift and antigenic shift that enables it to escape 
from protective immunity. Influenza infection in humans is self-limiting, but the virus is known to cause substantial 
mortality and morbidity worldwide2. During the most devastating influenza pandemic of 1918 the global mortality 
reached to 50 million individuals in one year. In a stark reminder to the 1918 pandemic, the population that is 
considered fittest was the most vulnerable during the recent 2009 H1N1 pandemic3.  
 
Despite intensive efforts, the threat to influenza persists as there are many limitations to the use of existing vaccines 
and antiviral therapies. The protection provided by vaccines that contain killed or recombinant viral glycoprotein is 
weak and may last as little as 6 months. Moreover, the vaccine efficacy in immunocompromised and elderly 
individuals is only 39% 4. Above all the vaccines have to be formulated annually as the existing year’s vaccine may 
not provide protection to the newly emerging strains. Currently four antiviral drugs are approved for use against 
influenza virus but, their use is restricted due to possible side effects and rapid emergence of resistant strains in the 
recent years. Hence, the development of new therapeutic targets and strategies to control pandemic and seasonal 
influenza virus infection in humans is urgently needed. 
 
 Passive immunotherapy against influenza has been reported since the 1918 influenza pandemic, where convalescent 
sera was used for treating patients5. However, use of convalescent plasma is being largely replaced with monoclonal 
antibody preparations owing to the recent advances in monoclonal antibody engineering. There are several reports 
where antibody therapy using polyclonal and monoclonal antibodies has been used effectively as prophylaxis against 
varicella, hepatitis A, hepatitis B, rabies, and respiratory syncytial virus infections6.  
 
The use of human mAb or humanized mAb to key epitopes of infectious pathogens may help in defining the humoral 
responses with significant therapeutic potential. The use of human mAbs may also lead to more effective post exposure 
prophylaxis including their use intranasally in viral diseases7. Human monoclonal antibody technology has seen 
various advances recently, like the use of Epstein Barr virus (EBV) to transform human B cells, development of 
several new heteromyeloma cell lines and CpG oligonucleotides that further enhance the efficiency of B cell 
transformation8. 
 
In this study, we generated strongly neutralizing novel human monoclonal antibodies that were selected from the 
immune repertoire of influenza infected seropositive patients. We generated two stable monoclonal antibody secreting 
fusion clones that produced antibodies specific against A(H1N1)pdm09 virus. We further investigated the in vivo 
prophylactic and therapeutic efficacy of these monoclonal antibodies against influenza A virus infection in the in vivo 
model. This study supports the fact that fully human mAbs with neutralization activity can be successfully generated 
from the peripheral blood of convalescent patients under optimized conditions.  
 
2. Materials and Methods 
   2.1 Cells  and viruses 
  Madine Darby Canine Kidney (MDCK) cells were procured from the National Centre for Cell Science (NCCS), 
Pune, India. EBV transformed marmoset leukocyte cell line (B95-8) was a kind gift, from Dr. Rahul Pal, NII, Delhi. 
The HMMA2.5 human mouse heteromyeloma was provided by Dr. Lisa Cavacini, Beth Israel Deaconess Medical 
Centre, Boston, USA.  Pandemic virus reference strain A/Cal/07/2009 (H1N1) was procured from Victoria infectious 
disease reference laboratory (VIDRL), Australia.   
 
2.2 Collection and processing of the clinical samples 
Eight A(H1N1)pdm 2009 seropositive patients (5 males and 3 females) within the age range of 20-50 years (median 
= 36 years) were recruited in this study. RNA was isolated from the nasal and throat swab samples and influenza virus 
infection was detected by real time RT PCR. All the volunteers had low Ct (cycle threshold) values (below 25) for 
influenza approximately 3-4 weeks after onset of the disease.  15 ml blood samples were collected in heparanized 
vacutainers from these donors. 1-2 ml plasma samples were collected from each sample and stored at - 80°C for 
serological examination. The remaining blood was used for PBMC isolation. 
  
2.3 Hemagglutination inhibition (HAI) assay of the plasma samples 
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Plasma samples were treated with Receptor destroying enzyme (RDE) for the destruction of non-specific inhibitors. 
Serial two fold dilution of the plasma samples was prepared in PBS in a microtiter plate.The plasma samples (diluted 
1:10) were added in equal volume (25 μl) of 4HA units of A/Cal/07/2009(H1N1). Plates were covered and incubated at 
room temperature (RT) for 30 min. The contents of the plate were mixed by gently agitating the plates manually.50 μl 
of the 0.75% guinea pig RBCs were added to each well. Plates were covered and incubated at RT for 30 min. The HAI 
titre was the highest dilution of the serum that showed hemagglutination activity. 
 
2.4 Generation of monoclonal antibodies from PBMCs 
The monoclonal antibodies were generated from the PBMCs of infected patients by the method as per Gorny M, 
19948, with minor modifications. Mononuclear cells were isolated from the blood of the seropositive patients by 
density gradient centrifugation and were resuspended in the EBV transformation medium (B95-8 culture supernatant 
that was diluted 1:2 with complete medium (RPMI+ 20% FCS) to a concentration of 2 x 106 cells/ml in the presence 
of CpG ODN-2006 (1μg/ml)9 and were cultured overnight at 37°C. After three weeks of culture, proliferating 
transformed colonies of B lymphocytes were observed using an inverted microscope10. The positive clones were 
screened by microneutralization11 and expanded to T-25 tissue culture flasks. The positive clones were fused with 
HMMA2.5 (at a ratio of 1:3) cell lines by adding 1 ml of warm PEG/DMSO solution dropwise for 1 min. The cell 
culture supernatant of the stable clones was collected and the monoclonal antibodies were subsequently purified by 
affinity chromatography by Protein G columns (Sigma Aldrich, USA). 
 
2.5 Immunoflourescence 
Madin Darby Canine Kidney (MDCK) cells were grown in 24 wells tissue culture plates, at a density of 0.1 x 106 cells 
per well for 24h.Cells were infected with 100 TCID50 units of A (H1N1) pdm2009 virus. 24 h after infection, cells 
were fixed with acetone: methanol (1:1) for 1 min, followed by permeabilization with Triton X 100. Fixed cells were 
blocked with 2% BSA in PBS for 1 h at 4 °C and washed twice with PBS. Monoclonal antibodies were added at a 
concentration of 5 μg/ml and the plates were incubated for 2h at 4 °C. Plates were washed thrice with PBS. Bound 
antibodies were detected with FITC labeled goat anti-human IgG and observed under an immunofluorescent 
microscope3. 
 
  2.6 Hemagglutination inhibition (HAI) assay  
Hemagglutination inhibition assay of the purified monoclonal antibodies was performed by the end point dilution 
method11. Two fold serial dilutions of the purified monoclonal antibodies were taken, with the maximum concentration 
of 2.5μg/ml. The HAI titers were expressed as the lowest concentration of the antibody that completely inhibited 4HA 
units of the pandemic virus.  
 
2.7  Microneutralization assay  
Microneutralization assay of the purified antibodies was performed by the end point dilution method11. Briefly, two 
fold serial dilutions of the antibodies were prepared in PBS starting with the highest dilution of 2.5μg/ml in 96 well 
tissue culture plates. 100 TCID50 of the pandemic isolate as well as reference strain12 were incubated with equal volume 
of the antibody for 1 h at 37°C. 100 μl MDCK cells (1.5 x 105 cells/ml) were added to each well. The plates were 
incubated for 3-4 days at 37 °C in 5% CO2 and examined for CPE. The residual infectivity was tested in four wells 
per dilution. The neutralizing titer was determined as the lowest concentration of the antibody at which the infectivity 
of 100 TCID50 of the respective virus for MDCK cells was completely neutralized in 50% of the wells. Infectivity was 
identified by the presence of cytopathic effect on day 4 and the titer was calculated by the Reed-Muench method12. 
 
2.8 Immunoblot analysis 
The infected cell lysates were first resolved on 12% SDS-PAGE and then transferred to PVDF membrane using Trans-
Blot SD Semi-Dry Transfer Cell (Bio-Rad Laboratories, CA, USA). The membrane was blocked with 5% non-fat 
milk in TBST for 2 h at room temperature and was washed thrice with TBST. The blot was then cut into strips and 
denatured antigens were probed by incubating each strip with a single purified monoclonal Ab at a concentration of 
1μg/ml. Anti-human IgG was taken as the negative control. The strips were then washed thoroughly with 1X TBST 
for three times, 10 min each, followed by incubation with 1:1000 dilution of horse-radish peroxidase (HRP) conjugated 
goat anti-human IgG as secondary antibody (diluted in 5% milk-TBST) for 1 h at room temperature. After washing, 
the immuno-reactive bands were visualized by the addition of PBS containing 10 μl/ml of 30 % H2O2 and 0.5 mg/ml 
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of DAB (Sigma Aldrich, USA).  
 
2.9 Characterization of the antibodies in vivo 
To evaluate the degree of protection of monoclonal antibodies, 6-8 weeks old female BALB/c mice (n=8 per group) 
were intraperitoneally injected with purified monoclonal antibodies in three different concentrations (2μg, 20μg, 200 
μg), 2h before (pre), 24 h after (24 h post) and 48 h after (48 h post) challenge with 2 X 104  PFU A/Cal/07/2009 
(H1N1) virus. Mice were monitored daily for sickness, weight loss and death for 21 days. 
 
2.10 Statistical analysis 
Significance of the differences between means was determined by Student t test using Graph Pad Prism software 
version 3.02 (San Diego, CA, USA). The results were presented as mean + S.D. 
 
3. Results 
3.1 Profiling of the patient plasma 
 
Plasma samples of all the donors showed serologic reactivity with the HA of the reference pandemic strain as was 
evident with the hemagglutination inhibition assay and showed a titer of <1:40.The individual titers of the plasma 
samples are mentioned in table I. 
 
Table I: Serologic testing of the eight volunteers (reciprocal titers are mentioned) 
 
Donor 
number 
1                2                 3                   4                  5               6                    7                          8
Plasma 
titer 
640          160              640               160               1280          320             320                   160
 
 
 
3.2 Generation of antibodies from the PBMCs 
PBMCs from all the eight seropositive volunteers were transformed with EBV and the supernatants of the transformed 
colonies were screened by microneutralization assay for the influenza virus specific antibodies (Table II). The positive 
clones were fused with the HMMA2.5 heteromyeloma cells. After fusion only two stable fusion clones secreting 
neutralizing monoclonal antibodies against the pandemic virus were established.  
 
Table II: Characteristics of the screening of EBV transformed B-cell cultures with A(H1N1)pdm09 virus. 
Number of influenza infected patients 8 
Total number of PBMCs isolated (million) 1 64.1 
Number of wells plated2 672 
Number of wells positive for antibodies against influenza virus3 53 
Number of influenza virus antibody secreting stable fusion clones4 4 
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1 PBMCs of all 8 patients were successfully transformed with EBV. The mean of PBMCs isolated from patients was 
8.0 million per individual (range 3.9-10.2). 
2 PBMCs were plated in 96 well tissue culture plates at 80,000—100,000 cells per well.  
3    approximately 7.2% wells (49/672) were positive for neutralizing antibodies against their autologus virus. 
4 Both the clones 2D8 and  2F12 clones were derived from separate donors (donor 7 and donor 5 respectively). 
Most of the transformed colonies lost reactivity in subsequent rounds of screening due to possible out-growth of non-
secretors and instability in antibody generation. The mAbs were purified by affinity chromatography on protein G 
columns. 
3.3 Binding of monoclonal antibodies to the whole virus by ELISA 
The monoclonal antibodies were analyzed in vitro by a series of assays.2D8 and 2F12 bound to the pandemic virus 
A/Cal/07/2009 on ELISA in a dose dependent manner. 2F12 showed lesser binding compared to the 2D8 antibody 
(Figure 1). Similar results were obtained when the two monoclonal antibodies were tested for their binding to the HA of 
a panel of viruses selected for the HAI assay. The mAbs showed binding to the reference pandemic strain as well as the 
laboratory isolate but did not show binding to any other H1N1 or H3N2 virus they were tested against. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
           Figure 1: Relative binding of monoclonal antibodies 2D8 and 2F12 to A/Cal/07/2009 (H1N1) influenza virus. 
 
Table III: HAI specific activity of the monoclonal antibodies (μg/ml) against a panel of H1N1 and H3N2 viruses. 
Influenza virus used Subtypes  
Concentrations of antibodies used (μg/ml) 
2D8 2F12 
pdm09 (H1N1) isolate 
A/Cal/07/2009  
A/Udorn/307/1972 
A/PR/8/34 
A/Perth/16/2009 
H1N1 
H1N1 
H3N2 
H1N1 
H3N2 
0.04 
0.08 
> 
> 
> 
1.8 
1.3 
> 
> 
> 
>Indicates that HAI activity was not detected at any concentration that was tested up to 2.5μg/ml. 
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The immunofluorescence data further supported the above findings that 2D8 bound more strongly to influenza virus 
infected MDCK cells compared to the 2F12 mab (Figure 2). 
 
 
 
 
 
 
 
Figure 2: Immunofluorescence Assay of the A/Cal/07/2009 
infected MDCK cells showing the binding of monoclonal antibodies 2D8 and 2F12. 
 
3.4 Western blot analysis of the purified antibodies 
The gel was run in the denaturing condition, to allow HA protein to denature to HA1 and HA2. Antibody 2D8 reacted 
with the denatured viral HA1 protein as was evident by a band at 49kDa (Figure 3). In contrast antibody 2F12 showed 
no binding activity to the denatured HA1.It may be hypothesised that 2F12 that did not show binding to any region in 
the denatured HA protein, as it might be recognizing a conformational epitope. 
 
 
 
 
 
 
 
 
 
Figure 3: Western blot analysis of monoclonal antibodies. Band corresponding to the HA1 region were observed in the 
lysate of MDCK cells infected with A(H1N1)pdm09 virus with monoclonal Abs 2D8 but was not observed with 2F12 
antibody.  
 
3.5 Characterization of the monoclonal antibodies in vivo 
Mice were treated with graded doses (200μg, 20 μg, and 2 μg) of the two mAbs (2D8 and 2F12), 2h pre, 24 h post and 48 
h post infection with the respective strains of influenza viruses as mentioned in the methods section. The antibodies were 
evaluated for their prophylactic or therapeutic efficacy by the assessment of morbidity (loss of weight), mortality, viral load 
and histopathologic examination of the lungs. The survival and weight loss experiments suggested that the mAb 2D8 
achieved considerable protection at the doses 20 μg and 200 μg when administered prophylactically and therapeutically 
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(table IV). The 2F12 mAb was more effective at the dose of 200 μg. Viral load analysis was performed in the subgroups 
2h pre and 24 h post challenge with 20 μg mAb. The lung virus titers of the treated mice confirm that upon treatment 
with the mAbs, the virus titer considerably reduces in the lungs (Table V).  
 
Table IV: Therapeutic and prophylactic efficacy of the monoclonal antibodies against A(H1N1)pdm09 influenza 
virus. 
Antibody Virus inoculated Dose per 
mouse 
(μg) 
Weight loss  
(%) 
Survival  
(no. of protected/total no.) 
2h pre* 24 h 
post# 
48 h 
post^ 
2h  
pre        
24 h 
post     
48 h 
post 
2D8 
 
 
2F12 
 
 
Control 
human 
IgG 
A(H1N1)pdm09 
 
 
A(H1N1)pdm09 
 
 
A(H1N1)pdm09 
200 
20 
2 
2.5 
10 
14 
4.3 
11 
14 
5.0 
14 
15 
5/5 
5/5 
0/5 
5/5 
5/5 
0/5 
5/5 
5/5 
0/5 
200 
20 
2 
4.5 
14 
16 
5.5 
15 
15 
6.6 
14 
18 
4/5 
3/5 
0/5 
5/5 
3/5 
0/5 
5/5 
2/5 
0/5 
200 
20 
2 
10 
15 
18 
12 
12 
17 
11 
16 
19 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
0/5 
*Monoclonal antibody treatment was given 2 h before infection with the virus. 
#Monoclonal antibody treatment was given 24 h after inoculation with the virus  
^Monoclonal antibody treatment was given 48 h after infection with the virus 
 
 
Table V: Pulmonary virus titers in the lungs of infected mice (2 X 104 PFU) after treatment with monoclonal 
antibodies. 
Monoclonal 
antibody 
Virus inoculated Virus titers (PFU/ml)  
 
2h pre 
 
24 h post 
 
48 h post 
 
2D8 
2F12 
Control IgG 
A(H1N1)pdm09 
A(H1N1)pdm09 
A(H1N1)pdm09 
(1.2±0.4)x102 
(1.5±0.4)x103 
(2.0±0.4)x105 
(1.5±0.6)x102 
(2.0±0.4)x103 
(2.02±0.4)x105 
ND 
ND 
ND 
*ND-Not determined 
 
Subsets of the mice with therapeutic treatment (24 h) were killed on the fourth day of infection for histopathologic 
evaluation. Without treatment the lungs showed degenerative changes with dense neutrophilic 7nfiltrates and diffuse 
alveolar damage. Passive immunization with either of the two mAb considerably reduced the pathologic changes and 
offered protection to the lungs from the lethal challenge of influenza virus (Figure 4). 
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Figure 4: Treatment with monoclonal antibodies 2D8 and 2F12 diminishes lung damage associated with viral infection 
caused by A/Cal/07/2009 (H1N1) virus. 
 
 
4. Discussion 
The production of human monoclonal antibodies is a much more complex procedure than the production of murine 
monoclonal antibodies. Scarcity of antibody producing cells in the peripheral blood and the difficulty to obtain the blood 
from naturally infected patients at the right time is one of the major concerns. Moreover, EBV transformed B cells are 
hard to grow and secrete very low amount of antibodies13. The instability of antibody production by Epstein-Barr virus 
transformed cells or fused cells is another concern. These factors result in the decreased fusion efficiency and the chances 
of obtaining a human hybridoma against an antigen of interest is only of the order of 10-9 to10-10.  
The human hybridoma technology is based on two main methods: fusion of Ab producing B cells to myeloma cells 14 
and transformation of B lymphocytes with EBV15. Combination of both the methods has proved to be more beneficial 
than either of them alone16. In this study, we report the generation of two stable fusion clones, secreting monoclonal 
antibodies against A(H1N1)pdm09  influenza viruses. The conditions of EBV transformation and fusion with the 
heteromyeloma cell line were optimised by overcoming the limitations of the current technologies.   
The convalescent phase plasma of the eight influenza positive patients was screened for influenza virus specific 
antibodies, as the serum/plasma antibody titre is a critical factor for the generation of monoclonal antibodies from 
PBMCs. The PBMCs were EBV transformed in the presence of CpG oligonucleotides as it has been reported to increase 
the rate of EBV transformation17. An overall 7.8% transformation efficiency was achieved and the cells that were positive 
for antibodies against the pandemic H1N1 virus were fused with HMMA2.5 cells. 
The best antibody secreting hybrids were cloned at one cell /well to ensure monoclonal antibody generation and 2 stable 
fusion clones were obtained- 2D8 and 2F12 that secreted mAbs against A(H1N1)pdm09 and showed neutralization in 
the in vitro as well as in vivo conditions. 
Monoclonal antibody 2D8 showed the maximum binding in the in vitro assays and neutralized the human isolate of the 
pandemic strain as well as the reference strain at lowest concentrations when compared to the 2F12 antibody. MAb 2F12 
showed the lesser binding in ELISA and immunofluorescence assay and although it showed HAI and neutralizing 
activity, but at a higher concentration compared to the 2D8 antibody. The western blot analysis of the monoclonal 
antibodies revealed that 2D8 bound to the HA1 region in the denatured HA protein. 2F12 did not show binding to any of 
the region in the denatured HA protein. Hence, it is hypothesised that 2F12 may be binding a conformational epitope in 
the HA1 region. However, the binding properties of 2F12 need to be investigated further to confirm the hypothesis. 
The monoclonal antibodies did not show binding to the seasonal H3N2 or any other H1N1 or H3N2 virus against which 
its HAI activity was determined. The reference strains available in the laboratory were picked randomly for the HAI 
studies. Further studies regarding the mapping of the epitope of these antibodies can reveal more information on whether 
or not they exhibit cross reactivity to other influenza virus strains. The antibodies however, showed comparative 
neutralization and HAI activity between the laboratory isolates of the pandemic virus and the reference strain 
A/Cal/07/2009(H1N1). This data reflects the fact that these Indian pandemic isolates have not shown much deviation 
from the prototype pandemic strain in terms of antibody binding sites. 
The prophylactic and therapeutic efficacy of these antibodies was determined in mice. The antibody treatment was given 
2 h before, 24 h after and 48 h after challenge with the pandemic strain. The in vivo results were consistent with the in 
vitro study and all the antibodies were able to considerably protect mice from lethal influenza challenge. Both the 
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antibodies were protective prophylactically but, 2F12 could achieve only 60% protection in terms of survival assay at 20 
μg, but achieved 100% survival rate at 200μg. The antibodies were less protective 48 h post infection as compared to 24 
h, the fact that is supported by the survival assays and weight loss percentage. The histopathologic examination of the 
lungs was done in the group of mice that were treated therapeutically at 24h The hisptopathology data further supported 
the survival and morbidity results, as the lungs from the mice that were given therapeutic doses of the antibodies, showed 
considerably less signs of alveolar damage and neutrophilic infiltrates resulting from virus infection. 
The antibodies 2D8 and 2F12 may be employed as therapeutic agents for at least 48 h after influenza infection as is 
indicated by the studies in mice. To, the best of our knowledge, these antibodies are the first fully human monoclonal 
antibodies generated from the immune repertoire of Indian patients infected with A(H1N1)pdm09 virus. Molecular 
characterization of their epitopes with Indian pandemic isolates will reveal more information of their cross-protectivity 
and binding characteristics. The strength of our approach for antibody generation lies in the fact that it has used human 
immune repertoire rather than animals and the antibodies have been generated in response to a natural infection of 
influenza virus. Since, the antibodies have originated from humans, self -reactivity against self- antigens is minimised in 
comparison to antibodies that have been generated in mice or through the technique of phage display. 
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